Sleep Aids Market, By Product Type (Medications, Sleep Apnea Devices, Mattresses and Pillows, and Others), By Sleep Disorder (Insomnia, Sleep Apnea, Restless Legs Syndrome, Night Terrors, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024

Code : CMI1059

Pages :187

Formats :

Excel and PDF

Industry : Medical Devices

Key Developments

On February 13, 2024, ResMed, a medical device company, announced that it had launched its AirCurve 11 series. The AirCurve 11 series is combined with digital tech to help treat sleep apnea. The AirCurve 11 is a bi-level positive airway pressure (PAP) that provides higher pressure during inhalation and lower pressure during exhalation. As per the company, the design lets the device align more closely with natural breathing patterns.
In November 2023, The DeRUCCI Group, a public company and sleep technology brand, launched the DeRUCCI T11 Pro Smart Mattress, an artificial intelligence of things (AIoT) intelligent sleep solution
In January 2022, Eisai Co., Ltd., a pharmaceutical company, announced that the U.S. Food and Drug Administration, approved Dayvigo (lemborexant) for the treatment of insomnia
In June 2021, Eisai Co., Ltd., a research-based pharmaceutical company that develops, manufactures, and commercializes high quality medicines, launched an in-house developed drug DAYVIGO (LEMBOREXANT) in Hong Kong, China. DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm for the treatment of insomnia. In addition, applications for approval have been submitted to the respective regulatory authorities in Australia, Brazil, India, Indonesia, and other countries.
In August 2021, ResMed, a company which provides an innovative solution in sleep technology for obstructive sleep apnea, snoring solutions, hypertension & respiratory care solutions, launched an AirSense 11 PAP Series, Personal Therapy Assistant, and Care Check-In for treating sleep apnea.